The ARTIST Trial is now enrolling! ARTIST is a randomized study comparing TAVR with the Trilogy THV to SAVR in non-high-risk patients with moderate-to-severe and severe aortic regurgitation. Visit https://t.co/wMdTuMe2ZY to learn more about Aortic Regurgitation and the ARTIST

The ARTIST Trial is underway! This randomized study is comparing TAVR with the Trilogy Transcatheter Heart Valve to SAVR in non-high-risk patients with moderate-to-severe or severe AR. Visit https://t.co/wMdTuMe2ZY to learn more. CAUTION: Investigational Device. Limited by

🚨 Late-Breaking Trial at #LondonValves2025! Join Dr. Raj Makkar at #LondonValves2025 for the highly anticipated Late-Breaking Trials presentation: “TAVI for Aortic Regurgitation in High Surgical Risk: Outcomes in 700 Patients from ALIGN-AR.” New insights from the ALIGN-AR

📍JenaValve is excited to join the global structural heart community at #PCRLondon Valves 2025. 📅November 16–18. Stop by our booth and discover how the Trilogy Heart Valve System brings innovation and new possibilities to the treatment of aortic regurgitation.

🎉 Milestone Moment! 🎉 We’re proud to celebrate 1,000 Trilogy THV implants across Europe! This achievement marks another step forward in advancing treatment for patients with severe aortic regurgitation. A special thank you to Drs. Stephan Baldus, Matti Adam, Victor Mauri and

JenaValve announces a live case from the ARTIST Trial presented at TCT 2025 by Dr. Raj Makkar (Cedars-Sinai Medical Center), highlighting the latest advancements in transcatheter treatment for aortic regurgitation. This milestone underscores the continued clinical progress of

We’re excited to join the cardiothoracic surgery community at STSA 2025! Stop by our booth to learn more about the ARTIST Trial, a randomized study evaluating TAVR with the Trilogy THV versus SAVR in non-high-risk patients with moderate-to-severe and severe aortic regurgitation.

The JenaValve team has arrived at #TCT2025!🫀 Swing by Booth #2143 to meet the team and learn more about our commitment to advancing care in aortic regurgitation. CAUTION: Investigational Device. Limited by Federal (or US) law to investigational use only. Not available for

🔴 LIVE from TCT 2025! 🔴   Join us for a live TAVR in aortic regurgitation case from the ARTIST Trial — the first randomized study comparing TAVR vs. SAVR in non–high-risk patients with moderate-to-severe and severe aortic regurgitation.   📍 Structural Live Case Arena | Hall F

Join us at #TCT2025 for an in-depth look at the future of aortic regurgitation management. From advanced imaging to surgical repair to the latest in transcatheter therapies, leading experts will share insights that are reshaping the way we approach AR. Sunday, October 26th

San Francisco, here we come! We’re thrilled to be part of #TCT2025 and connect with the interventional cardiology community. Stop by our booth #2143 to meet the JenaValve team, learn about the Trilogy Transcatheter Heart Valve, and explore our commitment to advancing innovation

JenaValve is heading to St. Louis for the 7th Annual Heart Team Summit! We’re excited to share updates on the ARTIST Trial and engage in discussions about advancing care for AR patients. Stop by our booth to learn more! 📅 October 3-4, 2025 📍 St. Louis, Missouri

The ARTIST Trial is now enrolling patients with significant aortic regurgitation (AR). This randomized study is comparing TAVR with the Trilogy Transcatheter Heart Valve to SAVR in non high-risk patients with moderate-to-severe or severe AR. Patients: See if you may qualify

Aortic regurgitation is a common and deadly disease, yet remains underdiagnosed and undertreated. https://t.co/wMdTuMe2ZY is a trusted resource for patients and physicians to learn about AR and explore treatment options through the ARTIST Trial. 🔗Click the link to learn

🚨 Guideline Update from @escardio 2025🚨 Earlier Intervention in Asymptomatic Severe AR The 2025 ESC/EACTS Guidelines introduce important updates to the thresholds for intervention in asymptomatic severe aortic regurgitation (AR): ✅Surgery may be considered in patients with

We're excited to be attending the 2025 Piedmont Heart Valve Symposium! Stop by the JenaValve Table to learn more about the ARTIST Trial and explore the latest developments in aortic regurgitation care. Our team looks forward to connecting and sharing insights in structural heart

🫀Heading to Nashville for #ASE2025? Don't miss the latest in aortic regurgitation care: from echocardiographic diagnostic dilemmas and multimodality imaging with MRI and CT, to surgical and lifetime management strategies, and emerging transcatheter therapies. Tune-in to this

🚨 Guideline Update from @escardio 2025🚨 The newly released 2025 ESC/EACTS Guidelines bring an important change for the management of severe aortic regurgitation (AR): ✅ TAVI may be considered for symptomatic patients with severe AR who are not candidates for surgery. ✅

JenaValve will be attending the ASE 2025 Scientific Sessions! 🫀 @ASE360 is Harmonizing Hearts and bringing together leaders in echocardiography and cardiovascular imaging to advance innovation, research, and collaboration. For diseases like aortic regurgitation, imaging plays

📢 New Publication in @JACCJournals : Cardiovascular Imaging “Staging of Cardiac Adverse Remodeling in Moderate or Severe Aortic Regurgitation” by @MaanMalahfji and colleagues. In this prospective study, the authors investigate a proposed cardiac remodeling staging system for